US 12,454,726 B2
Combinations, detection methods and kits of DNA methylation biomarker
Ruan Weimei, Guangzhou (CN); Jiang Zeyu, Guangzhou (CN); Li Xia, Guangzhou (CN); Chen Zhiwei, Guangzhou (CN); and Fan Jianbing, Guangzhou (CN)
Assigned to AnchorDx Medical Co., Ltd., Guangzhou (CN)
Filed by AnchorDx Medical Co., Ltd., Guangzhou (CN)
Filed on Nov. 8, 2023, as Appl. No. 18/504,402.
Application 18/504,402 is a continuation of application No. 17/036,424, filed on Sep. 29, 2020, granted, now 11,851,714.
Application 17/036,424 is a continuation in part of application No. PCT/CN2020/072770, filed on Jan. 17, 2020.
Claims priority of application No. 201911367385.4 (CN), filed on Dec. 26, 2019; and application No. 202010506210.3 (CN), filed on Jun. 5, 2020.
Prior Publication US 2024/0084398 A1, Mar. 14, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); C12Q 1/6806 (2018.01); G16B 5/00 (2019.01)
CPC C12Q 1/6886 (2013.01) [C12Q 1/6806 (2013.01); G16B 5/00 (2019.02); C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/154 (2013.01)] 6 Claims
 
1. A method for assessing bladder cancer risk in a human subject, comprising:
performing bisulfite treatment of a DNA of a urine sample obtained from said subject;
conducting methylation-specific quantitative PCR to amplify the DNA to obtain a CT value for at least one CpG region of the sequence of SEQ ID NO: 3, or the complementary sequence of SEQ ID NO: 3;
determining if bladder cancer is present in the subject based on comparing the obtained CT value of the at least one CpG region of the sample with a predetermined range of CT value of the at least one CpG regions, wherein the predetermined range of CT value was derived from a statistical analysis of a training set of samples including samples in which bladder cancer is present and samples in which bladder cancer is not present; and
treating the bladder cancer in the subject if it is determined that bladder cancer is present in the subject.